4.5 Review

Preventing Alzheimer's Disease Separating Fact From Fiction

期刊

CNS DRUGS
卷 22, 期 11, 页码 887-902

出版社

ADIS INT LTD
DOI: 10.2165/00023210-200822110-00001

关键词

-

资金

  1. Eisai Pharmaceuticals, Humanetics and Elan
  2. [AG05138]
  3. [AG10483]
  4. [AG15922]
  5. NATIONAL INSTITUTE ON AGING [P50AG005138, U01AG010483, U19AG010483, R01AG015922] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Alzheimer's disease is an ever-increasing health concern among the aging population, and as we research new and existing treatments for this disease we begin to uncover possibilities for its prevention. Observational studies and animal models have provided promising findings and generated excitement, but placebo-controlled clinical trials are required to demonstrate true efficacy for these treatments. In the past two decades, clinical trials have led to the approval of symptomatic treatments for Alzheimer's disease, including cholinesterase inhibitors and, more recently, an NMDA receptor antagonist. Clinical trials have also examined antioxidants, NSAIDs, hormone replacement, nutritional supplements and non-pharmacological interventions for the treatment and prevention of Alzheimer's disease. While the results of many of these trials have been disappointing, new mechanisms targeting the hallmark pathology of Alzheimer's disease are currently under investigation, including immunotherapy and secretase modulation, targeted at reducing the amyloid burden, for which we await the results. We review the evidence from completed trials, support for ongoing studies and propose directions for future research.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据